CompanyGraph
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
300204 · SZSE · China
staidson.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.84B, above the global median of $1.15B
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.40BCNY1.84B · vs all stocks (USD)
Revenue (TTM)
203.92MCNY30.29M · vs all stocks (USD)
Profit Margin
-41.13%vs Biotechnology peers
Beta
0.4520xvs all stocks
52-Week Change
-57.19%vs all stocks
Market Capitalization
12.40BCNY1.84B · vs all stocks (USD)
Enterprise Value
11.88BCNY1.76B · vs all stocks (USD)
Forward P/E
31.48xvs Biotechnology peers
Price to Sales (TTM)
64.35xvs Biotechnology peers
Price to Book (MRQ)
14.30xvs Biotechnology peers
Enterprise to Revenue
58.27xvs Biotechnology peers
Enterprise to EBITDA
-194.62xvs Biotechnology peers
Gross Margin
78.19%vs Biotechnology peers
Profit Margin
-41.13%vs Biotechnology peers
Operating Margin
-11.88%vs Biotechnology peers
Return on Assets (TTM)
-4.34%vs Biotechnology peers
Return on Equity (TTM)
-10.70%vs Biotechnology peers
Revenue (TTM)
203.92MCNY30.29M · vs all stocks (USD)
Revenue per Share (TTM)
0.4270CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-25.80%vs Biotechnology peers
Gross Profit (TTM)
157.16MCNY23.34M · vs all stocks (USD)
EBITDA (TTM)
-61.06MCNY-9.07M · vs all stocks (USD)
Net Income (TTM)
-83.86MCNY-12.45M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-26.52%vs Biotechnology peers
Operating Cash Flow (TTM)
-130.31MCNY-19.35M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-163.39MCNY-24.27M · vs all stocks (USD)
5-Year Average Dividend Yield
2.40%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-14.06MCNYFY2025 · Dec 31, 2025Revenue
220.23MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
50.08MCNYFY2025 · Dec 31, 2025Gross Profit
170.15MCNYFY2025 · Dec 31, 2025Operating Income
-78.41MCNY-11.65M · vs all stocks (USD)
Pre-tax Income
-88.32MCNYFY2025 · Dec 31, 2025Income Tax Expense
-216.59KCNYFY2025 · Dec 31, 2025Net Income
-88.11MCNYFY2025 · Dec 31, 2025EBIT
-79.83MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-54.50MCNYFY2025 · Dec 31, 2025Research & Development
84.94MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
90.81MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
832.24KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.49MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
486.02MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
486.02MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-88.11MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.34MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-147.09MCNYFY2025 · Dec 31, 2025Free Cash Flow
-221.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
123.22MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-88.11MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.31MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-61.69MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.61MCNYFY2025 · Dec 31, 2025Capital Expenditures
-74.42MCNYFY2025 · Dec 31, 2025Sale of Investments
21.42MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-52.99MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
80.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-30.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.09MCNYFY2025 · Dec 31, 2025Other Financing Charges
199.72MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
248.64MCNYFY2025 · Dec 31, 2025Shares Outstanding
477.77MSharesUpdated Aug 19, 2026Float Shares
275.05MSharesUpdated Aug 19, 2026% Held by Insiders
38.23%vs all stocks
% Held by Institutions
8.19%vs all stocks
Total Cash (MRQ)
128.28MCNY19.05M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2690CNYUpdated Aug 19, 2026Total Debt (MRQ)
119.78MCNY17.79M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1507xvs Biotechnology peers
Current Ratio (MRQ)
2.00xvs Biotechnology peers
Book Value per Share (MRQ)
1.70CNYUpdated Aug 19, 2026Total Assets
1.27BCNY188.06M · vs all stocks (USD)
Total Current Assets
252.65MCNYFY2025 · Dec 31, 2025Total Liabilities
459.48MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.01BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
283.94MCNYFY2025 · Dec 31, 2025Total Current Liabilities
175.55MCNYFY2025 · Dec 31, 2025Cash
123.64MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.74KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
123.64MCNYFY2025 · Dec 31, 2025Accounts Receivable
24.13MCNYFY2025 · Dec 31, 2025Inventory
19.30MCNYFY2025 · Dec 31, 2025Accounts Payable
21.92MCNYFY2025 · Dec 31, 2025Short-term Debt
80.49MCNYFY2025 · Dec 31, 2025Other Current Liabilities
31.86MCNYFY2025 · Dec 31, 2025Long-term Debt
667.20KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
207.27MCNYFY2025 · Dec 31, 2025Common Stock (Book)
477.77MCNYFY2025 · Dec 31, 2025Retained Earnings
-496.53MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
806.72MCNY119.81M · vs all stocks (USD)
52-Week Low
18.98CNYUpdated Aug 19, 202652-Week High
65.36CNYUpdated Aug 19, 202652-Week Change
-57.19%vs all stocks
Beta
0.4520xvs all stocks
50-Day MA
23.16CNYUpdated Aug 19, 2026200-Day MA
26.81CNYUpdated Aug 19, 2026Avg 10-Day Volume
39.49MSharesUpdated Aug 19, 2026Avg 30-Day Volume
41.82MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.1800CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.78Profit Margin: -0.41
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.77
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.84B, above the global median of $1.15BNotable
Market cap (USD): 1,841,974,587.014Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Netflix, Inc.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Henan Splendor Science & Technology Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Kingnet Network Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated